No Data
No Data
Liberal Arts Biotech (300294): Performance is in line with expectations, optimistic about the company's future growth space
Core idea: The company released its 2024 quarterly report. 2024Q1 achieved revenue of 448 million yuan (-44.36%, the following are year-on-year figures), net profit to mother of 152 million yuan (-10.74%),
China Post Securities released a research report on April 25 stating that it gave Liberal Arts Biotech (300294.SZ) a purchase rating. The main reasons for the rating include: 1) blood products are expected to maintain good growth, and the amount of pulp c
China Post Securities released a research report on April 25 stating that it gave Liberal Arts Biotech (300294.SZ) a purchase rating. The main reasons for the rating include: 1) blood products are expected to maintain good growth, and the amount of pulp collected is expected to increase further throughout the year; 2) excellent profitability, and the products under development are progressing steadily. (Mainichi Keizai Shimbun)
Liberal Arts Biotech (300294): Divestment of a subsidiary focusing on blood products led to fluctuations in performance
The 1Q24 results are in line with our expectations. The company announced 1Q24 results: revenue of 448 million yuan, down 44.36% year on year; net profit to mother was 152 million yuan, down 10.74% year on year, corresponding to earnings per share of 0.30
China Resources Pharmaceutical (03320): China Resources Liberal Arts Biotech's net profit for the first quarter of 152.2 million yuan decreased by 12.97% year-on-year
China Resources Pharmaceuticals (03320) announced that China Resources Biotech, a subsidiary of the company, will be 3 as of March 31, 2024...
Liberal Arts Biotech (300294): First-quarter results are in line with expectations, annual pulp harvesting is expected to increase at an accelerated pace
Incident: On April 24, the company released its 2024 quarterly report: the company achieved revenue of 448 million yuan, a year-on-year decrease of 44.36%; realized net profit of 152 million yuan, a year-on-year decrease of 10.74%; realized a year-on-year deduction
Liberal Arts Biotech (300294.SZ) announced first-quarter results, net profit of 152 million yuan, a decrease of 10.74%
Liberal Arts Biotech (300294.SZ) released its report for the first quarter of 2024, achieving 4.4 operating income during the reporting period...
No Data